BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 10739706)

  • 1. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
    Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
    Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.
    Gaarenstroom KN; Bonfrer JM; Korse CM; Kenter GG; Kenemans P
    Anticancer Res; 1997; 17(4B):2955-8. PubMed ID: 9329574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
    Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
    Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer.
    van de Lande J; Davelaar EM; von Mensdorff-Pouilly S; Water TJ; Berkhof J; van Baal WM; Kenemans P; Verheijen RH
    Gynecol Oncol; 2009 Jan; 112(1):119-25. PubMed ID: 19007978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
    Gadducci A; Tana R; Cosio S; Genazzani AR
    Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pre-treatment CYFRA 21 - 1 and SCC-Antigen assay in primary cervical carcinoma - a preliminary report.
    Puthucode-Easwaran S; Naik R; Athavale R; Handley G; Lopes A; Godfrey K; Hatem M
    J Obstet Gynaecol; 2005 Jul; 25(5):486-8. PubMed ID: 16183586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
    Gadducci A; Tana R; Fanucchi A; Genazzani AR
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S23-6. PubMed ID: 17727924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix.
    Bae SN; Namkoong SE; Jung JK; Kim CJ; Park JS; Kim JW; Lee JM; Kim SJ
    Gynecol Oncol; 1997 Mar; 64(3):418-24. PubMed ID: 9062143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk factors and prognosis of node-positive cervical carcinoma].
    Feng SY; Zhang YN; Liu JG
    Ai Zheng; 2005 Oct; 24(10):1261-6. PubMed ID: 16219145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
    Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A
    Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
    Reesink-Peters N; van der Velden J; Ten Hoor KA; Boezen HM; de Vries EG; Schilthuis MS; Mourits MJ; Nijman HW; Aalders JG; Hollema H; Pras E; Duk JM; van der Zee AG
    J Clin Oncol; 2005 Mar; 23(7):1455-62. PubMed ID: 15735121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
    Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
    Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of squamous cell carcinoma antigen as a predictor of nodal metastasis in cervical cancer.
    Takeshima N; Hirai Y; Katase K; Yano K; Yamauchi K; Hasumi K
    Gynecol Oncol; 1998 Mar; 68(3):263-6. PubMed ID: 9570978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma.
    Bolger BS; Dabbas M; Lopes A; Monaghan JM
    Gynecol Oncol; 1997 May; 65(2):309-13. PubMed ID: 9159343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Squamous cell carcinoma antigen serum levels as prognostic parameter in patients with early stage vulvar cancer.
    Hefler LA; Sliutz G; Leodolter S; Speiser P; Joura E; Reinthaller A; Kohlberger P
    Gynecol Oncol; 2005 Jun; 97(3):904-7. PubMed ID: 15894354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation of serum squamous cell carcinoma antigen with clinico-pathological features and prognosis of squamous cell carcinoma of uterine cervix].
    Xiong Y; Liang LZ; Zheng M; Wei M; Shen Y
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):29-33. PubMed ID: 17331418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of prognostic factors in patients with cervical squamous cell carcinoma of stage Ib and IIa].
    Chen L; Lü WG; Xie X; Chen HZ; Yu H; Ni XH
    Zhonghua Fu Chan Ke Za Zhi; 2005 Apr; 40(4):239-42. PubMed ID: 15924669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Squamous cell carcinoma antigen correlates with tumor burden but lacks prognostic potential for occult lymph node metastases in penile cancer.
    Hungerhuber E; Schlenker B; Schneede P; Stief CG; Karl A
    Urology; 2007 Nov; 70(5):975-9. PubMed ID: 18068457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.